News Results
There are 798,175 News Results
May 16, 2024
Chemtrade Logistics Income Fund (TSX: CHE.UN) (“Chemtrade” or the “Fund”) today announced results for the three months ended March 31, 2024. The financial statements and MD&A will be available on...
May 23, 2024
Biomarker Analyses from Pivotal Phase 3 CLEAR Trial in Patients with Advanced Renal Cell Carcinoma Will Be Featured in an Oral Presentation
Jul 31, 2024
Hess Corporation (NYSE: HES) today reported net income of $757 million, or $2.46 per share, in the second quarter of 2024, compared with net income of $119 million, or $0.39...
Aug 20, 2024
RYBREVANT(® )plus LAZCLUZE(TM) is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib
Sep 4, 2024
Late-breaking results from the Phase 3 LEAP-012 trial offer further insight into the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma (HCC); data are selected for ESMO Presidential Symposium Session
Sep 8, 2024
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT(®) plus LAZCLUZE(TM) regimen compared to osimertinib monotherapy as first-line therapy
Sep 10, 2024
Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT(®), a three-fold reduction from 67.4 percent historically seen with standard IRR management
Sep 14, 2024
Post-progression outcomes showed significant and sustained improvement for RYBREVANT(®) plus standard of care versus chemotherapy alone
Sep 19, 2024
Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT(®) this year, with four indications overall
Oct 16, 2024
Woodside Energy Group (ASX: WDS) (NYSE: WDS) (LSE: WDS): Woodside CEO Meg O’Neill said: “We would like to acknowledge the tragic death in early October of an employee of one...
